Primary central nervous system lymphoma—current standards and recent developments
Open Access
- 23 February 2026
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (4) , 640-648
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare aggressive B-cell non-Hodgkin lymphoma confined to the central nervous system, without systemic involvement. The incidence has increased over the past 3 decades. The prognosis has improved in patients up to 70 years old, and this type of lymphoma can be potentially cured. The gold standard of diagnosing PCNSL is histological, usually on a brain biopsy specimen via a neurosurgical procedure. Recent developments in both imaging and laboratory analyses of the cerebrospinal fluid, can be helpful in narrowing the differential diagnosis, diagnosing PCNSL itself, and in follow-up after treatment. This narrative review gives an overview of the epidemiology, diagnosis, and treatment of PCNSL, with an emphasis on recent developments in diagnostic techniques and treatment.Keywords
This publication has 75 references indexed in Scilit:
- Primary Diffuse Large B‐Cell Lymphoma of the Central Nervous System—Outcomes in Finland: A Nationwide Population‐Based StudyeJHaem, 2025
- Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalitionHemaSphere, 2025
- Whole brain radiotherapy combined with CART-cell therapy for relapsed/refractory central nervous system B-cell lymphomaAnnals of Hematology, 2025
- Primary central nervous system lymphomaJournal of Neurology, 2023
- Differentiation between glioblastoma and primary CNS lymphoma: application of DCE-MRI parameters based on arterial input function obtained from DSC-MRIEuropean Radiology, 2021
- Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell TransplantJAMA Oncology, 2021
- Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysisHematological Oncology, 2019
- Primary lymphoma of the central nervous system—a diagnostic challengeHematological Oncology, 2013
- Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphomaActa Neuropathologica, 2011